Landogrozumab

Drug Profile

Landogrozumab

Alternative Names: LY-2495655

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cachexia; Muscular atrophy; Pancreatic cancer
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Muscle-wasting(In volunteers) in USA (IV, Infusion)
  • 01 Jan 2016 Eli Lilly completes a phase II trial in Pancreatic cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater)/ Cachexia in USA, Canada, Israel, Norway, United Kingdom and Belgium (IV) (NCT01505530)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top